Overview

Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Alzheimer's disease is characterised by memory loss and difficulties with thinking. These problems may be due to a deficiency in a brain chemical called acetylcholine. Acetylcholine helps transmit messages between nerve cells. Acetylcholine is degraded by an enzyme called "acetylcholinesterase". ZT-1 is a new drug derived from a plant extract already used in China for memory disorders, which blocks the action of the enzyme and restores adequate levels of acetylcholine. This study will test the safety and efficacy of ZT-1 in the treatment of patients with Alzheimer's disease. BRAINz stands for Better Recollection for Alzheimer's patients with the Implant of ZT-1.
Phase:
N/A
Details
Lead Sponsor:
Debiopharm International SA
Treatments:
Donepezil